Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 20, 2025 08:30 ET | Source: AEON Biopharma Inc

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling
October 23, 2025 04:30 ET | Source: Custom Market Insights

[Latest] Global Radiopharmaceutical CDMO Market Size/Share Worth USD 7.2 Billion by 2034 at a 9.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Radiopharmaceutical CDMO Market Size, Trends and Insights By Application...
August 21, 2025 12:30 ET | Source: Custom Market Insights

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Biologics and Biosimilars Market Size, Trends and Insights By Product Type...
August 13, 2025 06:00 ET | Source: Neuronascent, Inc.

Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions

BALTIMORE., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the Phase 1a trial in aged human subjects of its...
July 24, 2025 15:30 ET | Source: Custom Market Insights

[Latest] Global CRISPR Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, July 25, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “CRISPR Gene Editing Market Size, Trends and Insights By Product (Kits and...
April 10, 2025 09:12 ET | Source: Albatroz Therapeutics

Nature Communications Publishes Pivotal Data From Albatroz Therapeutics Demonstrating That Inhibiting Calnexin Alleviates Arthritis Symptoms and May Reverse Disease Progression

Nature study uncovers insights about the progression of osteoarthritis (OA) and rheumatoid arthritis; demonstrates therapeutic approach targeting Calnexin.
March 26, 2025 15:00 ET | Source: Custom Market Insights

[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Austin, TX, USA, March 27, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Fabry Disease Treatment Market Size, Trends and Insights By Treatment (Enzyme...
December 19, 2024 06:27 ET | Source: Introspective Market Research

Clinical Trial Outsourcing Market Expected To Reach USD 111.01 Billion by 2032, Growing at a CAGR of 8.7% From 2024-2032 | Introspective Market Research

United Kingdom, London, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Australian healthcare technology company Resonance Health completed the acquisition of 100% of clinical research center TrialsWest for a...
December 10, 2024 11:30 ET | Source: Custom Market Insights

[Latest] Global Gastrointestinal Endoscopy Devices Market Size/Share Worth USD 21,413.4 Million by 2033 at a 5.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Austin, TX, USA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Gastrointestinal Endoscopy Devices Market Size, Trends and Insights By Product...
November 21, 2024 09:24 ET | Source: Purdue Research Foundation

Eradivir’s EV25 therapeutic proven to reduce advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies

WEST LAFAYETTE, Ind., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company that licenses innovations from Purdue Research Foundation, has developed a patent-pending antiviral...